This may result from the fact that the onset of tau pathology precedes neurological damage, and the AD patients selected for this study were symptomatic with lower cognitive scores and were already in the later stages of the disease, when the “N” changes were more pronounced. The gene discussed is MAPT; the disease is Alzheimer disease.